Colonization of host niches is the first step in establishing infection. In mammalian hosts the mucosal surface is lined with microbes which form the host's natural flora. The natural flora protects the host from infection through competition for space and nutrients. To gain a selective advantage, some microorganisms have developed quorum-sensing systems allowing them to overcome the natural flora.
C. albicans is an opportunistic human pathogen and was the first eukaryote identified to have a QS system. In this system, farnesol is secreted into the environment in a biomass-dependent manner and, once reaching threshold concentrations, inhibits the yeast-to-hyphal transition (
25). Farnesol is thought to allow the release of yeast cells from fungal biofilms, promoting the spread of infection (
43). However, the mechanism by which this occurs is still unknown. We show here that farnesol can directly modulate the activity of the
C. albicans adenylyl cyclase, reducing cAMP output to inhibit morphogenesis. Until recently Ras1p was suggested to be the mediator of QS in
C. albicans. This hypothesis was based on the hydrophobicity of farnesol and on the fact that farnesol inhibits both the cAMP/PKA and Cek1p MAPK cascades, which are activated by the actions of Ras1p. However, we provide two lines of evidence that suggest that Ras1p is not the main target of farnesol. First, farnesol was able to inhibit morphogenesis induced through the actions of CO
2, which does not require Ras1p, and, second, we have shown
in vitro that farnesol is able to directly modulate the activity of Cyr1p. Therefore, we now propose a model () whereby farnesol directly inhibits the catalytic activity of Cyr1p to reduce cytoplasmic cAMP levels and inhibit hyphal formation. In support of this model, strains carrying alleles leading to constitutive activation of Ras1p, which are hyperfilamentous due to continued activation of Cyr1p, remain fully responsive to farnesol (
11).
C. albicans is also responsive to other QSMs including 3-oxo-C
12-HSL, secreted by
P. aeruginosa (
24).
In vitro biochemical studies confirm that this QSM also modulates the activity of Cyr1p directly, suggesting a conserved mechanism of action for QS in
C. albicans. However, the 12-carbon alcohol dodecanol, which has QS activity against
C. albicans, did not directly modulate the activity of Cyr1p even though its mechanism of action is dependent on the cAMP/PKA signaling cascade. However, as purification of full-length Cyr1p was unsuccessful, we cannot rule out that dodecanol inhibits the activity of Cyr1p at a site distal to that of the catalytic domain. This may include the leucine-rich region (LRR domain) which has previously been shown to directly interact with bacterial peptidoglycan to regulate cyclase activity (
58). From our
in vitro assays we also cannot rule out the involvement of effector proteins. For example, Cap1p has recently been shown to be required for cyclase activation under serum-inducing conditions (
59). However, Cap1p is dispensable for Cyr1p activity in response to CO
2 (
59), suggesting that any role played by Cap1p in response to QSMs is likely to be minor.
Dodecanol appears to inhibit hyphal development through a cAMP-dependent pathway involving the transcriptional hyphal suppressor Sfl1p (). Therefore, Cyr1p may be only one of the receptors responsible for QS in
C. albicans. In agreement with this, global transcriptional approaches and phenotypical screens have identified that the Cek1p MAPK, Tup1p, and the two-component histidine kinase cascade function in QS (
26,
29,
46,
47). Although it is possible that QSMs affect multiple pathways, basal concentrations of cAMP are required for activation of these pathways, making it hard to deduce the role each pathway plays. Furthermore, as molecular mechanisms are dissected in detail, more cross talk between the pathways is emerging. For example, the cAMP/PKA pathway has recently been shown to regulate the phosphorylation of Hog1p (
12). Therefore, inhibition of the cAMP/PKA pathway may impact the Cek1p-MAPK and Tup1p pathways through interactions which are currently unidentified. In agreement with this, Sfl1p is known to interact with Ssn6p to recruit the Ssn6p-Tup1p regulatory complex to promoters in
Saccharomyces cerevisiae (
9). Interactions between Sfl1p and the Ssn6p-Tup1p complex in
C. albicans have not been studied. Therefore, it is possible that Tup1p's involvement in QS is due to disruption of the Sfl1p-Ssn6p-Tup1p complex. However, the
tup1Δ mutant does not respond to either farnesol or dodecanol (
26), suggesting that Tup1p plays another role in response to farnesol.
Mosel et al. have shown that farnesol is effective in inhibiting
C. albicans morphogenesis at concentrations below 5 μM under certain conditions (
41). However, our biochemical studies suggest that the IC
50 of Cyr1p for farnesol is 17 μM. Although the IC
50 may appear higher than concentrations found
in vivo, our experiments were performed on a truncated protein in which several domains were absent that might be required for a full response to QS. Therefore, it might be possible that full-length Cyr1p would exhibit an IC
50 nearer to
in vivo concentrations. In addition, in
in vivo situations QSMs appear to work by affecting several pathways (see above), so it may be possible that under these circumstances, where all components of every pathway are present, QS occurs at a much lower concentration.
Farnesol is toxic to a number of organisms as a result of the production and accumulation of reactive oxygen species (ROS) (
34,
48,
49). ROS generation is due to inhibition of the electron transport chain (
37,
38), suggesting that farnesol targets the mitochondria. Although it has been reported that farnesol is not toxic to
C. albicans (
11,
25), farnesol can still promote ROS generation (
53) and have toxic side effects on
C. albicans (
30). Recently, it has been shown that farnesol can enhance resistance to ROS (
12,
57). Initially the enhanced resistance was hypothesized to be a result of the elevated ROS inducing the expression of genes essential for ROS protection. However, Deveau et al. recently showed that the ROS generation by farnesol is not required for farnesol's impact on oxidative stress resistance (
12). Here, we provide evidence that dodecanol, which has QSM activity against
C. albicans, also enhanced oxidative stress resistance in
C. albicans, suggesting that other QSMs may enhance
C. albicans protection against ROS.
In the human host, potential outbreaks of
C. albicans are controlled by circulating phagocytes, which kill the pathogen through the release of high concentrations of ROS. Therefore, infections resulting in an accumulation of fungal biomass, for example, in esophageal candidiasis, may be more resistant to phagocyte killing due to increased resistance to ROS provided by the elevated concentration of farnesol. Moreover,
C. albicans infections can be a mixture of fungal and bacterial species. For example, in cystic fibrosis patients
C. albicans is routinely isolated from the lungs along with
P. aeruginosa and
B. cenocepacia (
3,
6,
19,
44), both of which produce QSMs with activity against
C. albicans (
7,
24). Therefore, the combination of QSMs present may affect the ability of the circulating phagocytes to kill
C. albicans. In agreement with this, QSMs have been shown to inhibit macrophage ROS production and induction of macrophage apoptosis (
1). Therefore, QSMs play essential roles in morphogenesis, stress resistance, and virulence through modulation of the
C. albicans cAMP/PKA pathway. Further understanding of the molecular mechanisms of other QSMs (including the DSF, BDSF, and SDSF secreted by
Xanthomonas campestris,
B. cenocepacia, and
Streptococcus species, respectively) on
C. albicans morphogenesis will enhance our understanding of interkingdom communication and shed light on the effects QSMs may have on the immune response (
7,
54,
56).